Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia-A biochemical and neurochemical study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 5, 2007, Pages 1130-1138

  Bishnoi, Mahendra ^a   Chopra, Kanwaljit ^b   Kulkarni, Shrinivas K ^a,b  

^a PANJAB UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

Haloperidol; Neuronal damage; Orofacial dyskinesia; Zolpidem

Indexed keywords

CATALASE; CHLORPROMAZINE; DIAZEPAM; DOPAMINE; HALOPERIDOL; HOMOVANILLIC ACID; NORADRENALIN; SEROTONIN; SUPEROXIDE DISMUTASE; VANILMANDELIC ACID; ZOLPIDEM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN HOMOGENATE; CHEMICAL ANALYSIS; CORPUS STRIATUM; DOSE RESPONSE; DRUG ANTAGONISM; FEMALE; LIPID PEROXIDATION; MALE; NEUROCHEMISTRY; NEUROPROTECTION; NONHUMAN; OROFACIAL DYSKINESIA; RAT;

ANIMALS; ANTI-DYSKINESIA AGENTS; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; CATALASE; CHLORPROMAZINE; DIAZEPAM; DYSKINESIA, DRUG-INDUCED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HALOPERIDOL; HYPNOTICS AND SEDATIVES; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; NEOSTRIATUM; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; NITRIC OXIDE; PYRIDINES; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE;

EID: 34249283362     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.04.007     Document Type: Article

References (49)

1. Andreassen O.A., and Jorgensen H.A. Neurotoxicity associated with neuroleptics induced oral dyskinesia in rats, implications for tardive dyskinesia. Prog Neurobiol 65 (2000) 525-531
2. Araujo N.P., et al. Effects of topiramate on oral dyskinesia induced by reserpine. Brain Res Bull 64 (2005) 331-337
3. Balijepalli S., Kenchappa R.S., Boyd M.R., and Ravindranath V. Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics. Neurochem Int 38 5 (2001) 425-435
4. Bentareha R. Pharmacological properties of the GABA A receptor complex from brain regions of (hypoemotional) Roman high- and (hyperemotional) low-avoidance rats. Eur J Pharmacol 354 (1998) 91-97
5. Bester A.M., and Harvey B.H. Early suppression of striatal cyclic GMP may predetermine the induction and severity of chronic haloperidol-induced vacuous chewing movements. Metab Brain Dis 15 4 (2000) 275-285
6. Bishnoi M., Chopra K., and Kulkarni S.K. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur J Pharmacol 552 1-3 (2006) 55-66
7. Brown D.W., Graupner P.R., Sainsbury M., and Shertzer H.G. New antioxidants incorporating indole and indolinechromophores. Tetrahedron 25 (1991) 4383-4408
8. Burger M.B.E. Ebselen attenuates reserpine induced orofacial dyskinesia and oxidative stress in rat striatum. Prog Neuro Psychopharmacol Biol Psychiatry 27 (2003) 135-140
9. Burger M.B.E. Effect of age on reserpine induced orofacial dyskinesia possible protection of diphenyl diselenide. Brain Res Bull 64 (2004) 339-345
10. Burger M.B.E. Acute reserpine and sub-chronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats. Brain Res 1031 2 (2005) 202-210
11. Burger M.B.E. Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain. Pharmacol Biochem Behav 81 (2005) 608-615
12. Church W.H. Column chromatography analysis of brain tissue: an advanced laboratory exercise for neuroscience majors. J Undergrad Psychol Res 3 2 (2005) A36-A41 [Spring]
13. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 82 (1959) 70-77
14. Fang J., Lai C.T., and Yu P.H. Neurotoxic effect of 4-(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl (-pyridinium) (HP+), a major metabolite of haloperidol in the dopaminergic system in vitro and in vivo. Biog Amines 12 (1996) 125-134
15. Farver D.K., and Khan M.H. Zolpidem for antipsychotic-induced. Parkinsonism 35 4 (2001) 435-437
16. Fibiger H.C., and Lloyd K.G. Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends Neurosci 7 (1984) 462-464
17. Garcia-Santos G., et al. Antioxidant activity and neuroprotective effects of zolpidem and several synthesis intermediates. Free Radic Res 38 12 (2004) 1289-1299
18. Gunne L., Häggström J., and Sjöquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 309 (1984) 347-349
19. Harvey B.H., and Bester A.M. Withdrawal-associated changes in peripheral nitrogen oxides and striatal cyclic GMP after chronic haloperidol treatment. Behav Brain Res 111 1-2 (2000) 203-211
20. Harvey B.H., and Nel A. Role of aging and striatal nitric oxide synthase activity in an animal model of tardive dyskinesia. Brain Res Bull 61 4 (2003) 407-416
21. Kanner J., Harel S., and Granit R. Nitric oxide an inhibitor of lipid peroxidation by lipoxygenase, cyclooxygenase and hemoglobin. Lipids 27 (1992) 46-49
22. Kono Y. Generation of superoxide radical during auto-oxidation of hydroxylamine and an assay of superoxide dismutase. Arch Biochem Biophys 186 (1978) 189-195
23. Lipton S.A., Choi Y.B., Pan Z.H., Lei S.Z., Chen H.S.V., Sucher N.J., et al. A redox based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso compounds. Nature 364 (1993) 626-632
24. Lissi E.A., Faure M., Montoya N., and Videla L.A. Reactivity of indole derivatives towards oxygenated radicals. Free Radic Res Commun 15 (1991) 211-222
25. Lohr J.B. Oxygen radicals and neuropsychiatric illness: some speculations. Arch Gen Psychiatry 48 (1991) 1097-1106
26. Lohr J.B., Kuczenski R., and Niculescu A.B. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 17 (2003) 47-62
27. Lowry O.H., et al. Protein measurements with the Folin-phenol reagent. J Biol Chem 193 (1951) 265-275
28. Luck H. Catalase spectrophotometric method. Methods in enzymatic analysis (1963), Academic Press, New York
29. Mayo J.C., et al. Protection against oxidative protein damage induced by metal catalyzed reaction or alkylperoxylradicals: comparative effects of melatonin and other antioxidants. Biochem Biophys Acta 1620 (2003) 139-150
30. Naidu P.S., Singh A., and Kulkarni S.K. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms. Br J Pharmacol 136 2 (2002) 193-200
31. Naidu P.S., Singh A., and Kulkarni S.K. Quercetin, a bioflavonoid attenuated haloperidol induced orofacial dyskinesia. Neuropharmacology 44 (2003) 1100-1106
32. Naidu P.S., Singh A., and Kulkarni S.K. Effect of Withania somnifera root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunction. Phytother Res 20 2 (2006) 140-146
33. Nel A., and Harvey B.H. Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine. Behav Pharmacol 14 3 (2003) 251-255
34. Niddam R., et al. Auto radiographic localization of [3H] zolpidem binding sites in the rat CNS: comparison with the distribution of [3H] flunitrazepam binding sites. J Neurochem 49 (1987) 890-899
35. O'Kane R.L., et al. Na ({thorn})-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. A mechanism for glutamate removal. J Biol Chem 274 (1999) 31891-31895
36. Pastoris A., et al. Automated analysis of urinary catecholamines by high-performance liquid chromatography and on-line sample pretreatment. J Chromatogr B Biomed Appl 664 2 (1995) 287-293
37. Peixoto M.F., et al. Effects of GABAergic drugs on reserpine-induced oral dyskinesia. Behav Brain Res 160 (2004) 51-59
38. Poeggeler B., et al. Melatonin's unique radical scavenging properties-roles of its functional substituents as revealed by a comparison with its structural analogs. J Pineal Res 33 (2002) 20-30
39. Raghavendra V., Naidu P.S., and Kulkarni S.K. Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors. Brain Res 904 (2001) 149-152
40. See R.E. Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride. Neurosci Lett 129 (1991) 265-268
41. Shivakumar B.R., and Ravindranath V. Oxidative stress and thiol modification induced by chronic administration of haloperidol. J Pharmacol Exp Ther 265 (1993) 1137-1141
42. Singh A., Naidu P.S., and Kulkarni S.K. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia. Eur J Pharmacol 477 2 (2003) 87-94
43. Soares K., Rathbone J., and Deeks J. Gamma-amino butyric acid agonist's for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 18 (2004) CD000203
44. Tan S., Schubert D., and Maher R. Oxytosis: a novel form of programmed cell death. Curr Top Med Chem 1 (2001) 497-506
45. Trotti D., Danbolt C., and Volterra A. Glutamate transporters are oxidant-vulnerable: a molecular link between oxidative and excitotoxic neurodegeneration?. Trends Pharmacol Sci 19 (1998) 328-334
46. Tsai G.C., et al. Markers of glutamatergic transmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 155 (1998) 1207-1213
47. Wills E.D. Mechanism of lipid peroxide formation in animal tissues. Biochem J 99 (1966) 667-676
48. Wink D.A., et al. Antioxidant effects of nitric oxide. Methods Enzymol 301 (1999) 413-424
49. Zaulyanov L.L., Green P.S., and Simkins J.W. Glutamate receptor requirement for neuronal death from an oxygenation: an in vitro model for assessment of the neuroprotective effects of estrogens. Cell Mol Neurobiol 19 (1999) 705-718